« Back to Record
Citation APA

Snauwaert, S., Vanhee, S., Goetgeluk, G., Verstichel, G., van Caeneghem, Y., Velghe, I., Philippé, J., Berneman, Z. N., Plum, J., Taghon, T., Leclercq, G., Thielemans, K. M., Kerre, T., & Vandekerckhove, B. (2012). RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica, 97(10), 1539-1547. doi:10.3324/haematol.2012.065581


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/167934

Snauwaert, S., Vanhee, S., Goetgeluk, G., Verstichel, G., van Caeneghem, Y., Velghe, I., Philippé, J., Berneman, Z. N., Plum, J., Taghon, T., Leclercq, G., Thielemans, K. M., Kerre, T., & Vandekerckhove, B. (2012). RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica, 97(10), 1539-1547. doi:10.3324/haematol.2012.065581